In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical Use
The DOI matches its Crossref record.
Abstract
Analogues of human insulin designed to have improved absorption properties after subcutaneous injection have been prepared by recombinant DNA technology. Five rapidly absorbed analogues, being predominantly in mono‐ or di‐meric states in the pharmaceutical preparation, and a hexameric analogue with very low solubility at neutral pH and slow absorption, were studied. Receptor binding assays with HEP‐G2 cells showed overall agreement with mouse free adipocyte assays. Two analogues, B28Asp and A21Gly + B27Arg + B30Thr‐NH 2, had nearly the same molar in vitro potency as human insulin. Another two showed increased adipocyte potency and receptor binding, B10Asp 194% and 333% and A8His + B4His + B10Glu + B27His 575% and 511%, while B9Asp + B27Glu showed 29% and 18% and the B25Asp analogue only 0.12% and 0.05% potency. Bioassays in mice or rabbits of the analogues except B25Asp showed that they had the same in vivo potency as human insulin 1.00 IU = 6.00 nmol. Thus the variation in in vitro potency reflects the differences in receptor binding affinity. Relative to human insulin a low concentration is sufficient for a high affinity analogue to produce a given receptor complex formation and metabolic response. In conclusion, human insulin and analogues with markedly different in vitro potencies were equipotent in terms of hypoglycaemic effect. This is in agreement with the concept that elimination of insulin from blood and its subsequent degradation is mediated by insulin receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Insulin analogues and their potential in the management of diabetes mellitus
Bolli, G. B., Di Marchi, R. D., Park, G. D., Pramming, S., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051286 · Cited by 349
Tenerz, A., Norhammar, A., Silveira, A., Hamsten, A., Nilsson, G., Rydén, L., & Malmberg, K. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2770 · Cited by 139
Standardization of insulin immunoassays: report of the American Diabetes Association Workgroup
Marcovina, S., Bowsher, R. R., Miller, W. G., Staten, M., Myers, G., Caudill, S. P., Campbell, S. E., Steffes, M. W., & Workgroup, F. T. I. S. (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.082214 · Cited by 136
“Highly purified, recombinant human insulin provided by Novo Nordisk and Eli Lilly and Company with a potency of 6.0 nmol/IU or 28.7 IU/mg pure insulin was used as the basis for SI molar units of insulin, assuming a molecular mass of monomeric insulin of 5808 Da. A multiplication factor of 6.0 was used to convert conce…”
MethodInfluentialStaten, M. A., Stern, M. P., Miller, W. G., Steffes, M. W., Campbell, S. E., & Workgroup, F. T. I. S. (2010) · Diabetes Care · doi:10.2337/dc09-1206 · Cited by 102
Gelding, S. V., Coldham, N., Anyaoku, V., Heslop, K., Halliday, D., & Johnston, D. G. (1993) · Diabetic Medicine · doi:10.1111/j.1464-5491.1993.tb00101.x · Cited by 4
Metadata
- Authors
- Vølund, A., Brange, J., Drejer, K., Jensen, I., Markussen, J., Ribel, U., Sørensen, A. R., & Schlichtkrull, J.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 1991-11
- Volume
- 8
- Issue
- 9
- Pages
- 839-847
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2086619387
- Cited by
- 73
- References
- 0
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical Use. https://app.cochat.ai/papers/10.1111/j.1464-5491.1991.tb02122.x
- The paper
- Vølund, A., Brange, J., Drejer, K., Jensen, I., Markussen, J., Ribel, U., Sørensen, A. R., & Schlichtkrull, J. (1991). In Vitro and In Vivo Potency of Insulin Analogues Designed for Clinical Use. Diabetic Medicine. https://doi.org/10.1111/j.1464-5491.1991.tb02122.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.